1
|
Browne RB, Goswami N, Borah P, Roy JD. Study of Glabranin as an Inhibitor Against Prostate Cancer: Molecular Docking, Molecular Dynamics Simulation, MM-PBSA Calculation and QSAR Prediction. Indian J Clin Biochem 2023. [DOI: 10.1007/s12291-023-01134-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023]
|
2
|
Ma Y, Ren X, Patel N, Xu X, Wu P, Liu W, Zhang K, Goodin S, Li D, Zheng X. Nobiletin, a citrus polymethoxyflavone, enhances the effects of bicalutamide on prostate cancer cells via down regulation of NF-κB, STAT3, and ERK activation. RSC Adv 2020; 10:10254-10262. [PMID: 35498570 PMCID: PMC9050343 DOI: 10.1039/c9ra10020b] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2019] [Accepted: 02/26/2020] [Indexed: 12/15/2022] Open
Abstract
Natural products have shown potential to be combined with current cancer therapies to improve patient outcomes. Nobiletin (NBT) is a citrus polymethoxyflavone and has been shown to exert an anticancer effect in various cancer cells. We investigated the effects and mechanisms of NBT in combination with bicalutamide (BCT), a commonly used anti-androgen drug in prostate cancer therapy, on prostate cancer cells. Our results demonstrate that the combined treatment with NBT and BCT produces an enhanced inhibitory effect on the growth of prostate cancer cells compared to either compound alone. The synergistic action of NBT and BCT was confirmed using isobologram analysis. Moreover, this study has shown that NBT and BCT synergistically inhibited colony formation and migration as well as induced apoptosis. Mechanistic studies demonstrate that NBT and BCT combination reduced key cellular signaling regulators including: p-Erk/Erk, p-STAT3/STAT3 and NF-κB. Overall, these results suggest that NBT combination with BCT may be an effective treatment for prostate cancer.
Collapse
Affiliation(s)
- Yuran Ma
- School of Biotechnology and Health Sciences, Wuyi University Jiangmen Guangdong 529020 China
| | - Xiang Ren
- School of Biotechnology and Health Sciences, Wuyi University Jiangmen Guangdong 529020 China
| | - Nandini Patel
- Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey 164 Frelinghuysen Road Piscataway NJ 08854 USA +1-732-445-0687 +1-848-445-8069
| | - Xuetao Xu
- School of Biotechnology and Health Sciences, Wuyi University Jiangmen Guangdong 529020 China.,International Healthcare Innovation Institute (Jiangmen) Jiangmen 529020 Guangdong China
| | - Panpan Wu
- School of Biotechnology and Health Sciences, Wuyi University Jiangmen Guangdong 529020 China
| | - Wenfeng Liu
- School of Biotechnology and Health Sciences, Wuyi University Jiangmen Guangdong 529020 China.,International Healthcare Innovation Institute (Jiangmen) Jiangmen 529020 Guangdong China
| | - Kun Zhang
- School of Biotechnology and Health Sciences, Wuyi University Jiangmen Guangdong 529020 China.,International Healthcare Innovation Institute (Jiangmen) Jiangmen 529020 Guangdong China
| | - Susan Goodin
- Rutgers Cancer Institute of New Jersey New Brunswick NJ 08903 USA
| | - Dongli Li
- School of Biotechnology and Health Sciences, Wuyi University Jiangmen Guangdong 529020 China.,International Healthcare Innovation Institute (Jiangmen) Jiangmen 529020 Guangdong China
| | - Xi Zheng
- Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey 164 Frelinghuysen Road Piscataway NJ 08854 USA +1-732-445-0687 +1-848-445-8069.,Rutgers Cancer Institute of New Jersey New Brunswick NJ 08903 USA
| |
Collapse
|
3
|
Emad A, Cairns J, Kalari KR, Wang L, Sinha S. Knowledge-guided gene prioritization reveals new insights into the mechanisms of chemoresistance. Genome Biol 2017; 18:153. [PMID: 28800781 PMCID: PMC5554409 DOI: 10.1186/s13059-017-1282-3] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2017] [Accepted: 07/18/2017] [Indexed: 02/08/2023] Open
Abstract
BACKGROUND Identification of genes whose basal mRNA expression predicts the sensitivity of tumor cells to cytotoxic treatments can play an important role in individualized cancer medicine. It enables detailed characterization of the mechanism of action of drugs. Furthermore, screening the expression of these genes in the tumor tissue may suggest the best course of chemotherapy or a combination of drugs to overcome drug resistance. RESULTS We developed a computational method called ProGENI to identify genes most associated with the variation of drug response across different individuals, based on gene expression data. In contrast to existing methods, ProGENI also utilizes prior knowledge of protein-protein and genetic interactions, using random walk techniques. Analysis of two relatively new and large datasets including gene expression data on hundreds of cell lines and their cytotoxic responses to a large compendium of drugs reveals a significant improvement in prediction of drug sensitivity using genes identified by ProGENI compared to other methods. Our siRNA knockdown experiments on ProGENI-identified genes confirmed the role of many new genes in sensitivity to three chemotherapy drugs: cisplatin, docetaxel, and doxorubicin. Based on such experiments and extensive literature survey, we demonstrate that about 73% of our top predicted genes modulate drug response in selected cancer cell lines. In addition, global analysis of genes associated with groups of drugs uncovered pathways of cytotoxic response shared by each group. CONCLUSIONS Our results suggest that knowledge-guided prioritization of genes using ProGENI gives new insight into mechanisms of drug resistance and identifies genes that may be targeted to overcome this phenomenon.
Collapse
Affiliation(s)
- Amin Emad
- Carl R. Woese Institute for Genomic Biology, University of Illinois at Urbana-Champaign, Urbana, IL 61801 USA
| | - Junmei Cairns
- Department of Molecular Pharmacology and Experimental Therapeutics, Gonda 19, Mayo Clinic Rochester, 200, 1st St. SW, Rochester, MN 55905 USA
| | - Krishna R. Kalari
- Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905 USA
| | - Liewei Wang
- Department of Molecular Pharmacology and Experimental Therapeutics, Gonda 19, Mayo Clinic Rochester, 200, 1st St. SW, Rochester, MN 55905 USA
| | - Saurabh Sinha
- Department of Computer Science and Institute of Genomic Biology, University of Illinois at Urbana-Champaign, 2122 Siebel Center, 201N. Goodwin Ave, Urbana, IL 61801 USA
| |
Collapse
|
4
|
Coleman DJ, Van Hook K, King CJ, Schwartzman J, Lisac R, Urrutia J, Sehrawat A, Woodward J, Wang NJ, Gulati R, Thomas GV, Beer TM, Gleave M, Korkola JE, Gao L, Heiser LM, Alumkal JJ. Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor. Oncotarget 2016; 7:40690-40703. [PMID: 27276681 PMCID: PMC5130036 DOI: 10.18632/oncotarget.9816] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2016] [Accepted: 05/07/2016] [Indexed: 12/21/2022] Open
Abstract
Prostate cancer is the most commonly diagnosed and second-most lethal cancer among men in the United States. The vast majority of prostate cancer deaths are due to castration-resistant prostate cancer (CRPC) - the lethal form of the disease that has progressed despite therapies that interfere with activation of androgen receptor (AR) signaling. One emergent resistance mechanism to medical castration is synthesis of intratumoral androgens that activate the AR. This insight led to the development of the AR antagonist enzalutamide. However, resistance to enzalutamide invariably develops, and disease progression is nearly universal. One mechanism of resistance to enzalutamide is an F877L mutation in the AR ligand-binding domain that can convert enzalutamide to an agonist of AR activity. However, mechanisms that contribute to the agonist switch had not been fully clarified, and there were no therapies to block AR F877L. Using cell line models of castration-resistant prostate cancer (CRPC), we determined that cellular androgen content influences enzalutamide agonism of mutant F877L AR. Further, enzalutamide treatment of AR F877L-expressing cell lines recapitulated the effects of androgen activation of F877L AR or wild-type AR. Because the BET bromodomain inhibitor JQ-1 was previously shown to block androgen activation of wild-type AR, we tested JQ-1 in AR F877L-expressing CRPC models. We determined that JQ-1 suppressed androgen or enzalutamide activation of mutant F877L AR and suppressed growth of mutant F877L AR CRPC tumors in vivo, demonstrating a new strategy to treat tumors harboring this mutation.
Collapse
Affiliation(s)
- Daniel J. Coleman
- OHSU Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, U.S.A
| | - Kathryn Van Hook
- OHSU Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, U.S.A
| | - Carly J. King
- OHSU Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, U.S.A
- Department of Biomedical Engineering, Oregon Health & Science University, Portland, Oregon, U.S.A
| | - Jacob Schwartzman
- OHSU Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, U.S.A
| | - Robert Lisac
- OHSU Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, U.S.A
| | - Joshua Urrutia
- OHSU Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, U.S.A
| | - Archana Sehrawat
- OHSU Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, U.S.A
| | - Josha Woodward
- OHSU Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, U.S.A
| | - Nicholas J. Wang
- OHSU Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, U.S.A
- Department of Biomedical Engineering, Oregon Health & Science University, Portland, Oregon, U.S.A
| | - Roman Gulati
- Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington, U.S.A
| | - George V. Thomas
- OHSU Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, U.S.A
| | - Tomasz M. Beer
- OHSU Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, U.S.A
| | - Martin Gleave
- The Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada
| | - James E. Korkola
- OHSU Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, U.S.A
- Department of Biomedical Engineering, Oregon Health & Science University, Portland, Oregon, U.S.A
| | - Lina Gao
- OHSU Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, U.S.A
| | - Laura M. Heiser
- OHSU Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, U.S.A
- Department of Biomedical Engineering, Oregon Health & Science University, Portland, Oregon, U.S.A
| | - Joshi J. Alumkal
- OHSU Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, U.S.A
| |
Collapse
|